109 Combined Modality Conference: " Immune Therapy for Breast Cancer " (021722)

Dallas, TX US
February 17, 2022

The combined modality therapy approach, including the medical, surgical and radiation arms of cancer therapy, provides
the best treatment options for the management of a wide variety of cancer patients with complex problems. This course is
designed to educate an audience specializing in the care of cancer patients. This conference provides a forum for
multimodality interaction that promotes discussion of the most recent clinical research affecting patient care, as well as
bringing oncology specialists together to review cases and make recommendations for managing cancer patients.

Target Audience

Medical Radiation, and Surgical Oncologists; Radiologists; Pathologists; Urologists; Neurologists; UTSW Faculty, Fellows
and Residents in training; and private practice oncologists

Learning Objectives

At the conclusion of this activity, participants should be able to:

  1. Review the management of a diversified group of cancer patients through case presentations with pathologic and radiologic review and discussions by medical, radiation and surgical oncologists
  2. Distinguish the importance of the interaction of surgical, medical and radiation modalities in the treatment of these patients
  3. Present the most recent advances in cancer therapy and basic cancer research from a clinical and laboratory perspective, with an emphasis on new translational research approaches.
Course summary
Available credit: 
  • 1.00 AMA
  • 1.00 Attendance
Course opens: 
02/17/2022
Course expires: 
02/17/2022
Event starts: 
02/17/2022 - 7:30am CST
Event ends: 
02/17/2022 - 8:30am CST
Cost:
$0.00
Part of: 
109 DIVISION OF HEM/ONC: ONCOLOGY BOARD REVIEW CONFERENCE 2022
Add to calendar: 
UT Southwestern Medical Center
2201 Inwood Road
(NC) 8.212 Conference Room Seay
Dallas, TX 75235
United States
Course Director(s)

Amy Jones, M.D.

has no relevant financial relationships to disclose at this time.
Speaker(s)

Amy Jones, M.D.

has no relevant financial relationships to disclose at this time.

Heather McArthur, Heather McArthur, MD, MPH

has a financial relationship (Independent contractor) with Immunomedics;.
has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Independent contractor) with Daiichi-Sankyo;.
has a financial relationship (Independent contractor) with Crown Bioscience;.
has a financial relationship (Independent contractor) with Lilly;.
has a financial relationship (Independent contractor) with Seattle Genetics;.
has a financial relationship (Independent contractor) with Gilead;.
has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with Puma Biotechnology;.

Available Credit

  • 1.00 AMA
  • 1.00 Attendance

Price

Cost:
$0.00
Please login or create an account to take this course.